Terumo Corporation has completed its previously announced acquisition of OrganOx for nearly $1.5bn after meeting all necessary regulatory and closing requirements.
In August 2025, Terumo signed a definitive agreement to purchase the company.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
OrganOx, which originated from the University of Oxford in 2008, will now operate as Terumo’s wholly owned subsidiary.
OrganOx specialises in organ technology focused on improving outcomes for individuals with acute or chronic organ failure.
Its metra normothermic machine perfusion (NMP) platform is used to preserve donor livers outside the body before transplantation.
The technology is approved in Australia, Canada, Europe, and the US, and has been used in more than 6,000 liver transplants.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to OrganOx, the deal will bring together OrganOx’s expertise in organ perfusion with Terumo’s capabilities in medical technology.
The move is expected to support further research and development for evolving the metra platform beyond liver transplantation and widening the use of NMP for organ support applications.
OrganOx will also have access to Terumo’s global network, which is anticipated to accelerate commercial growth and extend its reach into new markets.
OrganOx CEO Craig Marshall said: “The global need for donor organs remains urgent, with thousands of patients each year dying while waiting for a transplant or facing the risk of a failed transplant.
“Our mission has always been to create a world where every organ counts. Joining Terumo will accelerate our ability to scale our operations more rapidly, enter new markets and ensure that more patients around the globe can benefit from our technologies.”
“This milestone reflects the extraordinary dedication of our team, whose commitment to innovation and patient outcomes brought OrganOx to this point. With Terumo’s partnership, we’re positioned to deliver even greater growth and impact.”
Earlier this year, OrganOx secured $142m in primary and secondary equity funding to support the expansion of its metra platform in the international organ technology sector.
